课题基金 / 基金详情

Optimizing Gram-positive bacteria as a candidate for targeted anti-tumor therapy

Optimizing Gram-positive bacteria as a candidate for targeted anti-tumor therapy
优化革兰氏阳性菌作为靶向抗肿瘤治疗的候选者
批准号:
10204711
负责人:
Bentley M. Shuster
金额:
$5.7万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-01 至 2023-06-30

项目摘要

项目成果

Bentley M. Shuster的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT Cancer is the second leading cause of death globally and many available treatments lack the safety and effica- cy sought by oncologists and patients alike. Major efforts have been made to use living organisms, such as bacteria, as vehicles to produce and deliver site-specific therapeutic payloads, however they are mostly cen- tered on Gram-negative bacteria. In this proposal, we aim to expand the list of candidates available for probi- otic cancer therapy by exploring the potential for species of Bacillus to colonize tumor microenvironments. Many Bacillus species are generally regarded as safe (GRAS) and as Gram-positives are capable of high pro- tein product secretion. Therefore, we will also aim to expand the genetic toolbox for model organism, Bacillus subtilis, in order to develop Gram-positive production hubs of anticancer therapies. Using the bacteria-in- spheroid coculture (BSCC) model, we can rapidly screen for optimal isolates and recombinant protein products and use in vivo mouse models for follow up experiments exploring only the high preforming candidate strains. With in vitro and in vivo approaches, we aim to develop novel, safe, and effective alternatives to treat tumor growth and increase the quality of cancer therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optimizing Gram-positive bacteria as a candidate for targeted anti-tumor therapy
海外基金